The prevalence of otitis media in 2–3 year old Cameroonian children estimated by tympanometry

Publication date: Available online 6 October 2018

Source: International Journal of Pediatric Otorhinolaryngology

Author(s): John Njuma Libwea, Marie Kobela, Paul Koki Ndombo, Ritva K. Syrjänen, Heini Huhtala, Ninying Fointama, Sinata Koulla-Shiro, Hanna Nohynek, J. Pekka Nuorti, Arto A. Palmu

Abstract

Background

Acute otitis media is a common illness in children under-five years of age and associated with major health care resources in high-income countries. However, there is paucity of data on its epidemiology and clinical presentation in low-income countries. We estimated the prevalence of otitis media and assessed risk factors among children in Cameroon.

Methods

A community-based cross-sectional prevalence study of otitis media (OM) was performed on randomly selected children aged 2–3 years in Yaoundé, Cameroon from March to June 2013. OM was assessed by clinical inspection for chronic suppurative otitis media (CSOM) and tympanometry for otitis media with effusion (OME). CSOM was defined as draining of the middle ear with duration of more than two weeks and OME was defined as a flat 'type B' tympanogram.

Results

Out of 529 children enrolled in the study, 433 (56% males) subjects with available tympanograms were evaluated. Altogether, 9.7% (42/433) of children met the case definition of CSOM, OME or its complications. This consisted of 3 (0.7%) children identified with unilateral CSOM; 7 (1.6%) children with bilateral OME; 31 (7.2%) with unilateral OME and 1 (0.2%) subject with unilateral dry tympanic membrane perforation.

Logistic regression analyses showed statistically significant association between OM and parental reporting of "current symptoms of upper respiratory tract infections", Prevalence Odds Ratio (POR) = 3.71; 95% CI = 1.69–8.14).

Conclusion

As many as two out of a hundred children between the ages of 2–3 years were affected by significant middle ear disease i.e. CSOM or bilateral OME. These data could be useful as a baseline for estimating the impact of pneumococcal conjugate vaccines (PCV13) introduced in July 2011 for infants in Cameroon.

https://ift.tt/2Pgz6Ck